Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand.
Drugs. 2019 Mar;79(4):477-481. doi: 10.1007/s40265-019-01073-5.
Esaxerenone (MINNEBRO™)-a novel oral, non-steroidal, selective mineralocorticoid receptor blocker-is being developed by Daiichi Sankyo for the treatment of hypertension and diabetic nephropathies. In January 2019, based on positive results from a phase III trial conducted in Japan in patients with essential hypertension, esaxerenone received marketing approval in Japan for the treatment of hypertension. This article summarizes the milestones in the development of esaxerenone leading to this first global approval for the treatment of hypertension.
依普利酮（MINNEBRO™）-一种新型口服、非甾体类、选择性盐皮质激素受体拮抗剂，由第一三共株式会社开发，用于治疗高血压和糖尿病肾病。2019 年 1 月，基于在日本进行的一项针对原发性高血压患者的 III 期临床试验的积极结果，依普利酮在日本获得批准上市，用于治疗高血压。本文总结了依普利酮开发过程中的重要里程碑，最终使其在全球范围内首次获批用于治疗高血压。
